Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire, Amiens
About this trial
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient over 18
Patient affiliated to a social security scheme
Patient who understands French
Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old.
Disqualifiers
Patients under legal protection
Patients with concomitant pulmonary embolism
Patient with proximal or distal deep vein thrombosis
Patient treated with anticoagulant therapy for another indication
Trial population
Patient with active cancer: * Cancer treatment within the last 6 months, * Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer. * The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy). * Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
risk (in %) of recurrence of VTE
risk of recurrence of VTE at 3-month follow-up in patients with cancer-associated SVT.
Time frame
at 3-month follow-upSecondary outcomes
1
association (%) between initial treatment and the risk of SVT recurrence
Time frame
at 3 months2
association (%) between initial treatment and the risk of SVT recurrence
Time frame
at 6 months3
association (%) between initial treatment and the risk of SVT recurrence
Time frame
at 12 months4
Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)
Time frame
at 12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov